RRC ID 81800
著者 Ma Y, Nakamoto S, Ao J, Qiang N, Kogure T, Ogawa K, Nakagawa M, Fujiwara K, Iwanaga T, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Chiba T, Kato J, Kato N.
タイトル Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus.
ジャーナル Int J Mol Sci
Abstract A functional cure of hepatitis B virus (HBV) infection or HB antigen loss is rarely achieved by nucleos(t)ide analogs which target viral polymerase. HBx protein is a regulatory protein associated with HBV replication. We thought to identify antiviral compounds targeting HBx protein by analyzing HBx binding activity. Recombinant GST-tagged HBx protein was applied on an FDA-approved drug library chip including 1018 compounds to determine binding affinity by surface plasmon resonance imaging (SPRi) using a PlexArray HT system. GST protein alone was used for control experiments. Candidate compounds were tested for anti-HBV activity as well as cell viability using HepG2.2.15.7 cells and HBV-infected human hepatocytes. Of the 1018 compounds screened, 24 compounds showed binding to HBx protein. Of the top 6 compounds with high affinity to HBx protein, tranilast was found to inhibit HBV replication without affecting cell viability using HepG2.2.15.7 cells. Tranilast also inhibited HBV infection using cultured human hepatocytes. Tranilast reduced HB antigen level dose-dependently. Overall, theSPRi screening assay identified novel drug candidates targeting HBx protein. Tranilast and its related compounds warrant further investigation for the treatment of HBV infection.
巻・号 23(19)
公開日 2022-10-10
DOI 10.3390/ijms231912015
PII ijms231912015
PMID 36233317
PMC PMC9569680
MeSH Antiviral Agents / metabolism Antiviral Agents / pharmacology Hep G2 Cells Hepatitis B* Hepatitis B virus* Hepatocytes / metabolism Humans Viral Regulatory and Accessory Proteins / metabolism Virus Replication ortho-Aminobenzoates / pharmacology
IF 4.556
リソース情報
ヒト・動物細胞 HeLa Hep G2